Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Philippe Nuss, Emmanuelle Corruble, Emmanuelle Baloche, Ricardo P. Garay & Pierre-Michel Llorca. (2022) Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyond. Expert Review of Neurotherapeutics 22:8, pages 639-653.
Read now
Read now
Ricardo P. Garay. (2021) Investigational drugs and nutrients for human longevity. Recent clinical trials registered in ClinicalTrials.gov and clinicaltrialsregister.eu. Expert Opinion on Investigational Drugs 30:7, pages 749-758.
Read now
Read now
Gopalkumar Rakesh, Chi-Un Pae & Prakash S. Masand. (2017) Beyond serotonin: newer antidepressants in the future. Expert Review of Neurotherapeutics 17:8, pages 777-790.
Read now
Read now
Silvia Cerri, Francesca Siani & Fabio Blandini. (2017) Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias. Expert Opinion on Investigational Drugs 26:7, pages 777-791.
Read now
Read now
Ricardo P. Garay, Carlos A. Zarate$suffix/text()$suffix/text(), Thomas Charpeaud, Leslie Citrome, Christoph U. Correll, Ahcène Hameg & Pierre-Michel Llorca. (2017) Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Review of Neurotherapeutics 17:6, pages 593-609.
Read now
Read now
Ricardo P. Garay & George T. Grossberg. (2017) AVP-786 for the treatment of agitation in dementia of the Alzheimer’s type. Expert Opinion on Investigational Drugs 26:1, pages 121-132.
Read now
Read now
William James Deardorff & George T. Grossberg. (2016) Pharmacotherapeutic strategies in the treatment of severe Alzheimer’s disease. Expert Opinion on Pharmacotherapy 17:13, pages 1789-1800.
Read now
Read now
Articles from other publishers (15)
Hayden M. Carder, Yong Wang & Alison E. Wendlandt. (2022) Selective Axial-to-Equatorial Epimerization of Carbohydrates. Journal of the American Chemical Society 144:26, pages 11870-11877.
Crossref
Crossref
Damiana Scuteri, Maria Tiziana Corasaniti, Paolo Tonin, Pierluigi Nicotera & Giacinto Bagetta. (2021) New trends in pharmacological control of neuropsychiatric symptoms of dementia. Current Opinion in Pharmacology 61, pages 69-76.
Crossref
Crossref
Monika Marcinkowska, Adam Bucki, Joanna Sniecikowska, Agnieszka Zagórska, Nikola Fajkis-Zajączkowska, Agata Siwek, Monika Gluch-Lutwin, Paweł Żmudzki, Magdalena Jastrzebska-Wiesek, Anna Partyka, Anna Wesołowska, Michał Abram, Katarzyna Przejczowska-Pomierny, Agnieszka Cios, Elżbieta Wyska, Kamil Mika, Magdalena Kotańska, Paweł Mierzejewski & Marcin Kolaczkowski. (2021) Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia. Journal of Medicinal Chemistry 64:17, pages 12603-12629.
Crossref
Crossref
Claudia Carrarini, Mirella Russo, Fedele Dono, Filomena Barbone, Marianna G. Rispoli, Laura Ferri, Martina Di Pietro, Anna Digiovanni, Paola Ajdinaj, Rino Speranza, Alberto Granzotto, Valerio Frazzini, Astrid Thomas, Andrea Pilotto, Alessandro Padovani, Marco Onofrj, Stefano L. Sensi & Laura Bonanni. (2021) Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions. Frontiers in Neurology 12.
Crossref
Crossref
Anees Bahji, Arthi Chinna Meyyappan & Emily R. Hawken. (2019) Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis. The Canadian Journal of Psychiatry 65:6, pages 365-376.
Crossref
Crossref
Ayman Antoun Reyad, Eriny Girgis & Raafat Mishriky. (2020) Efficacy and safety of brexpiprazole in acute management of psychiatric disorders. International Clinical Psychopharmacology 35:3, pages 119-128.
Crossref
Crossref
Christophe Michon, Choong-Min Kang, Sophia Karpenko, Kosei Tanaka, Shu Ishikawa & Ken-ichi Yoshida. (2020) A bacterial cell factory converting glucose into scyllo-inositol, a therapeutic agent for Alzheimer’s disease. Communications Biology 3:1.
Crossref
Crossref
Monika Marcinkowska, Joanna Śniecikowska, Nikola Fajkis, Paweł Paśko, Weronika Franczyk & Marcin Kołaczkowski. (2020) Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates. CNS Drugs 34:3, pages 243-268.
Crossref
Crossref
Ken-ichi YOSHIDA & Shu ISHIKAWA. (2019) Production of <i>scyllo</i>-Inositol: Conversion of Rice Bran into a Promising Disease-Modifying Therapeutic Agent for Alzheimer’s Disease. Journal of Nutritional Science and Vitaminology 65:Supplement, pages S139-S142.
Crossref
Crossref
Martin Cloutier, Marjolaine Gauthier‐Loiselle, Patrick Gagnon‐Sanschagrin, Annie Guerin, Ann Hartry, Ross A. Baker, Ruth Duffy, Keva Gwin & Myrlene Sanon Aigbogun. (2019) Institutionalization risk and costs associated with agitation in Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 5:1, pages 851-861.
Crossref
Crossref
William James Deardorff & George T. Grossberg. 2019. Psychopharmacology of Neurologic Disease. Psychopharmacology of Neurologic Disease
5
32
.
Khachen Kongpakwattana, Ratree Sawangjit, Itthipol Tawankanjanachot, J. Simon Bell, Sarah N. Hilmer & Nathorn Chaiyakunapruk. (2018) Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis. British Journal of Clinical Pharmacology 84:7, pages 1445-1456.
Crossref
Crossref
Kosei Tanaka, Ayane Natsume, Shu Ishikawa, Shinji Takenaka & Ken-ichi Yoshida. (2017) A new-generation of Bacillus subtilis cell factory for further elevated scyllo-inositol production. Microbial Cell Factories 16:1.
Crossref
Crossref
Ladislav Volicer, Leslie Citrome & Jan Volavka. (2017) Measurement of agitation and aggression in adult and aged neuropsychiatric patients: review of definitions and frequently used measurement scales. CNS Spectrums 22:5, pages 407-414.
Crossref
Crossref
Eugene O’Hare, Deaglan Page, William Curran, Jeong-Sup Hong & Eun-Mee Kim. (2017) A preclinical screen to evaluate pharmacotherapies for the treatment of agitation in dementia. Behavioural Pharmacology 28:2 and 3, pages 199-206.
Crossref
Crossref